These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 19938948

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
    Holtorf K.
    Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815
    [Abstract] [Full Text] [Related]

  • 6. Drospirenone and its antialdosterone properties.
    Genazzani AR, Mannella P, Simoncini T.
    Climacteric; 2007 Feb; 10 Suppl 1():11-8. PubMed ID: 17364593
    [Abstract] [Full Text] [Related]

  • 7. The rationale for a wider range of progestogens.
    Skouby SO.
    Climacteric; 2000 Dec; 3 Suppl 2():14-20. PubMed ID: 11379382
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen.
    Foidart JM, Faustmann T.
    Gynecol Endocrinol; 2007 Dec; 23(12):692-9. PubMed ID: 18075844
    [Abstract] [Full Text] [Related]

  • 13. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
    Palacios S, Foidart JM, Genazzani AR.
    Maturitas; 2006 Nov 20; 55(4):297-307. PubMed ID: 16949774
    [Abstract] [Full Text] [Related]

  • 14. Progestogen therapies: differences in clinical effects?
    Wiegratz I, Kuhl H.
    Trends Endocrinol Metab; 2004 Aug 20; 15(6):277-85. PubMed ID: 15358281
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE.
    Acta Endocrinol (Copenh); 1991 Aug 20; 125 Suppl 1():13-26. PubMed ID: 1801500
    [Abstract] [Full Text] [Related]

  • 17. The adverse effects of hormonal therapy.
    Bush TL.
    Cardiol Clin; 1986 Feb 20; 4(1):145-52. PubMed ID: 3518931
    [Abstract] [Full Text] [Related]

  • 18. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M, Simoncini T, Fuller S, Genazzani AR.
    Maturitas; 2008 Feb 20; 60(3-4):185-201. PubMed ID: 18775609
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.